PARP-Inhibitor Combination Treatments: Biomarker Testing, Safety, and Efficacy in a Rapidly Changing Metastatic Prostate Cancer (mPC) Landscape Grant

PARP-Inhibitor Combination Treatments: Biomarker Testing, Safety, and Efficacy in a Rapidly Changing Metastatic Prostate Cancer (mPC) Landscape Grant

Status: ACTIVE
Funder: Pfizer, Inc.
Amount: Up to US $350,000
Last Updated: August 04, 2025

Summary

Pfizer's competitive grant program invites proposals focused on enhancing healthcare professional knowledge in prostate cancer treatment, particularly through biomarker testing and the use of PARP inhibitors. The initiative aims to improve clinical practice guidelines, safety, and efficacy of treatments in a rapidly evolving landscape. Key areas of interest include integration of genetic testing, understanding treatment mechanisms, and fostering patient engagement in clinical trials, ultimately leading to better patient outcomes.

Overview

Competitive Grants Program Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Projects that will be considered for Pfizer support will focus on increasing healthcare professional knowledge and competence in the following areas: Guideline concordance and best practices for integration of testing into clinical practice, including: when to order testing and how to interpret results of biomarkers and genetic mutations (inclusive of all HRR mutations, i.e. BRCA and non-BRCA)the role of the multidisciplinary team in ordering testseducation on strategies to identify and remove barriers to appropriate testing for patients with prostate cancer.Emerging data on efficacy and safety regarding PARPi’s used in the treatment of mPC including better understanding of:The mechanism of action and the biological and clinical rationale for PARPi combinationsClinical safety, treatment sequencing and patient subgroup dataClinical data regarding PARPi combinations and how to mitigate associated side effects for optimal patient care, including but not limited to, the role of the multidisciplinary team in ongoing therapy management.Best practices for initiating guideline concordant care for patients with mPC in community healthcare settings for optimal therapy management of PARPi combinations in prostate cancer including but not limited to:implementation of genetic testing workflowsencouraging patient engagement in treatment decisions and clinical trial participation.

Eligibility

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.

Application Details

Independent Medical Education
Request for Proposals (RFP)
PARP-Inhibitor Combination Treatments: Biomarker Testing, Safety, and
Efficacy in a Rapidly Changing Metastatic Prostate Cancer (mPC) Landscape
Competitive Grant Program – Pfizer Internal Review Process
Date RFP Issued: June 26, 2025
I. Eligibility
Geographic Scope/Location of Project:
United States
Applicant Eligibility Criteria
• Applicant organizations to this RFP must be based in the United States.
• The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare
institutions (both large and small); professional organizations/medical societies; medical education companies;
and other entities with a mission related to healthcare professional education and/or healthcare improvement.
• Only organizations are eligible to receive grants, not individuals or physician-owned medical practices.
• If the project involves multiple departments within an institution and/or between different institutions /
organizations / associations, all institutions must have a relevant role and the requesting organization must have
a key role in the project.
• For projects offering continuing education credit in the United States, the requesting organization must be
accredited.
II. Requirements
General Area of Interest for this RFP:
Projects that will be considered for Pfizer support will focus on increasing healthcare professional knowledge and
competence in the following areas:
• Guideline concordance and best practices for integration of testing into clinical practice, including: when to
order testing and how to interpret results of biomarkers and genetic mutations (inclusive of all HRR mutations,
i.e. BRCA and non-BRCA), the role of the multidisciplinary team in ordering tests, and education on strategies
to identify and remove barriers to appropriate testing for patients with prostate cancer.
• Emerging data on efficacy and safety regarding PARPi’s used in the treatment of mPC including better
understanding of: 1) the mechanism of action and the biological and clinical rationale for PARPi combinations
and; 2) clinical safety, treatment sequencing and patient subgroup data
• Clinical data regarding PARPi combinations and how to mitigate associated side effects for optimal patient
care, including but not limited to, the role of the multidisciplinary team in ongoing therapy management.
• Best practices for initiating guideline concordant care for patients with mPC in community healthcare settings
for optimal therapy management of PARPi combinations in prostate cancer including but not limited to,
implementation of genetic testing workflows and encouraging patient engagement in treatment decisions and
clinical trial participation.
1

Examples of educational formats that will be considered under this RFP include but are not limited to:
• On-agenda educational sessions during live conferences
• Multi-company supported, stand-alone symposia
• Expert interviews recorded at live conferences, conference coverage reviews
• Online articles, newsletter articles, training courses, webinars
• Social media posted & linked content
• Videos, podcasts, infographics, animations
It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic
agents will not be considered.
Target Audience:
Community oncologists, urologists, oncology nurses and nurse practitioners, physician assistants, pharmacists, genetic
counselors, and other healthcare professionals involved in the care and treatment of patients with mCRPC.
Expected Approximate Monetary Range of Grant Applications:
Individual projects requesting up to $350,000 will be considered. The estimated total available budget related to this
RFP is $850,000. Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy),
and indirect costs. Multi-supported educational programs encouraged.
Key Dates:
• RFP release date: June 26, 2025
• Grant Application due date: August 21, 2025
Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5).
• Anticipated Grant Award Notification Date: Week of September 15, 2025
• Grants will be distributed following a fully executed agreement.
• Anticipated Approximate Project Start and End Dates: October 2025 to April 2027 (18 months preferred
maximum length; projects may be shorter than 18 months)
How to Submit:
Note: Please read this section carefully since applications submitted not following these instructions will not be accepted
and will be cancelled.
• Please go to www.cybergrants.com/pfizer/knowledge and sign in. First-time users should click “Create your
password”. [Note: there are individual portals for each grant application type. Please be sure to use the URL
above.]
• Click the “Start A New Knowledge Gap Application" button.
• In the application:
• For the question “What type of request are you submitting?” select Response to a Request for Proposal
(RFP)
• For the question “Are you replying to a Request for Proposal (RFP) as part of the Competitive Grant
Program?” select Yes
• Select the following Competitive Grant Program Name: 2025 ONC US PARPi mCRPC IME
• Select the following Primary Area of Interest: Oncology – Genitourinary - KG
• Requirements for submission:
Complete all required sections of the online application and upload your project proposal (see Appendix) in the
General RFP Submission field.
• If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the
bottom of the page.
IMPORTANT: Be advised applications submitted after the due date will not be reviewed.
2

Questions:
If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Lori Carpenter
(lori.carpenter@pfizer.com), with the subject line “2025 ONC US PARPi mCRPC IME”
Grant Agreements:
• If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer.
Please click here to view the core terms of the agreement.
• Under Pfizer’s competitive grant program, modifications to grant agreements will not be reviewed unless a
genuine conflict exists as between applicable law and the terms of the relevant grant agreement. Applicant is
encouraged to share the core terms with counsel for approval prior to submitting an application.
• Except where prohibited by applicable law and, in any case, subject to review by Pfizer Legal, payment of grant
funding may only be paid to the grantee organization.
• This RFP is supported by Pfizer Inc. and, if approved, payment will be sent from the United States.
Review and Approval Process:
Grant requests received in response to a general RFP are reviewed by Pfizer colleagues to make final grant decisions.
Mechanism by which Applicants will be Notified:
• All applicants will be notified via email by the dates noted above.
• Applicants may be asked for additional clarification during the review period.
About Pfizer External Research & Grants
Pfizer External Research & Grants (ER&G) supports the global healthcare community’s independent initiatives (e.g.,
research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are
aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s ER&G competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides
detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review
process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps
as outlined in the specific RFP.
For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the
design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in
any aspect of project development, nor the conduct of the independent education program.
3

Appendix
General RFP Submission Requirements
Applications will be accepted via the online portal listed in the How to Submit section. Project Proposals should be
single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references.
When uploading your Project Proposal please ensure it addresses the following sections:
Goals and Objectives
• Briefly state the overall goal of the project.
• List the objectives you plan to meet with your project, in terms of learning and expected outcomes.
Needs Assessment for the Project
• Include a description of your organization’s needs assessment for this proposed project which may include a
quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or
relevant patient-level data that informs the stated objectives) in your target area.
Target Audience
• Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the
project outcomes. Describe the overall population size as well as the size of your sample population.
Project Design and Methods
• Describe the planned project, the educational approach, and the way the planned methods address the established
need.
• Describe any plans as to how the content will be assessed to ensure it is up to date over the education
implementation and delivery lifecycle.
Innovation
• Explain what measures you have taken to assure that this project is original and does not duplicate other projects
or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing
projects developed either by your institution or other institutions.
Evaluation and Outcomes
• In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap
was addressed for the target group. Identify the sources of data your organization anticipates using to make the
determination. Describe how your organization is expected to collect and analyze the data. Explain the method
used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data).
Quantify the amount of change expected from this project in terms the target audience. Describe how your
organization will determine if the target audience was fully engaged in the project.
Dissemination Plan
• Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made
available to others to use? Will there be tools or resources that are made publicly available beyond the initial
project. Describe how the project outcomes might be broadly disseminated.
Anticipated Project Timeline
• Provide an anticipated timeline for your project including project start/end dates.
Additional Information
• If there is any additional information you feel Pfizer should be aware of concerning the importance of this project,
please summarize here.
4

Organization Detail
• Describe the attributes of the institutions / organizations / associations that will support and facilitate the execution
of the project and the leadership of the proposed project. Articulate the specific role of each partner in the proposed
project.
Budget Detail
• Please include a budget narrative that describes in greater detail the line items specified in the budget submitted
within the application.
• While estimating your budget please keep the following items in mind:
• Independent Medical Education Grants awarded by ER&G cannot be used to purchase therapeutic assets
(prescription or non-prescription).
• Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer. Please click
here for details. General organizational running costs such as legal fees, insurance, heating, and lighting etc.
should be included in an Institutional Overhead (if required). These costs are not specific to a grant request and
therefore, should not appear as line items in budgets. However, costs that are specific to the study (e.g., some
countries require insurance to be taken out on a per-study basis for clinical research) would be acceptable to
be included as line items.
5